-
Featured Authors
-
Archives
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Biobuck M&A in Full Gear
The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011. What was not down however was the earnout structures embedded in these deals. More and more M&A transactions are looking like partnering deals structured with CVRs accounting for the bolus of the reported purchase price. Here is a look at therapeutic-focused acquisitions (valued at >$10M) over the Read More >
Beantown Biotech: ‘Dominant Life Sciences Cluster’
Massachusetts’ Secretary of Housing and Economic Development, Greg Bialecki, was quoted in today’s Boston Herald as saying: “We are the dominant life sciences cluster in the world,” Greg Bialecki said, “and I don’t think that was an accident.” Thanks to the Gov. Deval Patrick administration’s support for bioscience economic development, his state has continued to grow and add biotech industry jobs as an economic engine. Boston’s biopharm industry is comprised of more than 500 companies Read More >
Auto Injectors & Pen Injectors: Differentiating Products in Asia Pacific
Asia Pacific, with its mix of mature and emerging pharmaceutical markets and strong indigenous R&D capabilities, has no doubt already become a prominent driving force for the current and future global pharmaceutical industry with reports projecting the industry in this region to grow at a CAGR of 10 percent between 2012 and 2015. As the third largest pharmaceutical market following North America and Europe, Asia Pacific offers an immense potential for multinational pharmaceutical companies not Read More >
A Big Year for Novel Drugs Approvals
What was your top Biopharma highlight for 2012? If it wasn’t the stellar move in the AMEX Biotech Index (up 42%), or the reauthorization of PDUFA, then perhaps it was the decade high for innovative drugs approvals. We would need to go back to the 1990s to find a year with as many FDA approvals for novel drugs as we had in 2012. Adding to the positive trend in numbers, up 29% from the robust Read More >
California Biomedical Companies Cite Lack Of Funding As Major Concern
As I have mentioned in past blog posts, the U.S. bioscience industry has demonstrated stability through turbulent economic times. While not immune from the recession, this industry generally fared much better than the overall economy and has remained a net a job generator. In April of 2012, the White House released the National Bioeconomy Blueprint noting that bioscience industries are “a large and rapidly growing segment of the world economy that provides substantial public benefit.” Read More >
